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Abstract: Background: Rash is the most common adverse effect associated with nevirapine (NVP). We aimed to develop 
a model and risk score for predicting NVP-associated rash among HIV-infected patients with low CD4 cell counts. 
Methods: Cross-sectional study was conducted and 383 HIV-infected patients consecutively enrolled in the study. 
Results: Of 222 patients in the training set, 116 (52.2%) were males and median (IQR) age was 35.2 (31.1-42.0) years. 
Median (IQR) CD4 cell count was 104 (35-225) cells/mm
3. Of these, 72 and 150 patients were in “rash” and “no rash” 
group, respectively. Four factors were independently associated with rash: a history of drug allergy (odds ratio (OR) 4.01, 
95% confidence interval (CI), 1.75-9.20, P = 0.001), body weight <55 kg. (OR 2.02, 95% CI, 1.09-3.76, p = 0.026), not 
receiving slow dose escalation (OR 2.00, 95% CI, 1.06-3.77, p = 0.032), and no concomitant drug(s) (OR 2.48, 95% CI, 
1.32-4.64, p = 0.005). Receiver-operator characteristic analysis yielded area under the curve of 71% and the goodness-of-
fit statistics was 6.48 (p = 0.840). The variables were given scores of 14, 7, 7 and 9, respectively. A cutoff >21 points 
defined the high risk individuals which yielded specificity and positive predictive value of 99% and 69%, respectively, 
with OR of 3.96 (95% CI, 1.79-8.86, p = 0.001). 
Conclusions: A model and risk score for predicting NVP-associated rash performed well in this study population. It might 
be useful for predicting the risk of rash before NVP initiation among HIV-infected patients with low CD4 cell counts. 
Keywords: HIV, model, nevirapine, prediction, rash, risk factor. 
INTRODUCTION 
  Some factors including patients’co-morbidity, adherence, 
convenience, adverse drug effects, drug-drug interactions, 
and pregnancy potential have to be considered when 
selecting an initial regimen of antiretroviral therapy (ART) 
for HIV-infected patients [1]. In addition, one should 
consider gender and pretreatment CD4 cell counts in case of 
nevirapine (NVP) initiation [1]. Use of non-nucleoside   
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reverse transcriptase inhibitor-based regimens as initial 
therapy can preserve protease inhibitors (PIs) for later use, 
thus reducing or delaying patient exposure to some of the 
adverse effects of PIs [1].  
  NVP is widely used as a component of the first-line ART 
in resource-limited countries because of the availability of 
generic drug at low cost and fixed-dose combination tablets. 
Nevertheless, NVP is not recommended to use in adult 
females with CD4 >250 cells/mm
3 and males with CD4 
>400 cells/mm
3 due to a high rate of hepatotoxicity [1]. 
Furthermore, the development of rash in HIV-infected 
individuals receiving NVP is the most common adverse 
effect especially during the first few weeks of therapy, with 
frequencies ranging from 9 to 32% [2-8]. Rare but serious 
hypersensitivity reactions, Stevens-Johnson Syndrome and 
toxic epidermal necrolysis, had been reported [5, 9, 10]. Risk 
factors for NVP-associated rash were female gender 
including pregnant women [11-14], lower body weight [15], 
initiation of NVP at high CD4 cell counts [11, 12, 15, 16], Prediction for Nevirapine-Associated Rash  The Open AIDS Journal, 2009, Volume 3    25 
pretreated with antiretroviral drugs less than 12 months [17], 
higher plasma NVP level [17], and genetic (human leukocyte 
antigen) [18, 19]. However, some factors may not be 
applicable to patients who were initiated NVP at low CD4 
cell counts in resource-limited settings. In addition, some 
risk factors differ among study population and from patients 
to patients.  
  NVP-associated rash can be minimized by escalating the 
initial dose of NVP or lead-in prescription [13, 20]. Despite 
this intervention, rash continues to be the leading cause of 
NVP discontinuation [21, 22]. Use of antihistamines and/or 
glucocorticoids cannot prevent this adverse effect [13, 23, 
24]. In some situations, NVP-based regimen is the only 
regimen that can be used, but one cannot predict the 
probability or risk of NVP-associated rash before NVP 
initiation for each particular individuals. We aimed to 
develop a model and risk score for predicting NVP-
associated rash among HIV-infected patients who were 
initiated NVP at low CD4 cell counts in resource-limited 
settings.  
METHODS 
  A cross-sectional study of HIV-infected patients, who 
attended the Infectious Diseases Clinic, Ramathibodi 
Hospital (a 1,000-bed University Hospital), Mahidol 
University, Bangkok, Thailand was conducted. Consecutive 
enrollment of patients had been done between March 2006 
and August 2007. Inclusion criteria were adult (>15 years 
old) HIV-infected patients and received a generic fixed-dose 
combination of stavudine, lamivudine, and NVP (GPO-
VIR
®). Each eligible patient was followed, at least, from 
initiating NVP until six weeks after NVP initiation. Rash 
associated with NVP was diagnosed by physicians. If 
patients received concomitant drugs, which also had a high 
possibility to cause rash and the diagnosis of causative drug 
was equivocal, these patients were not included in the study. 
Concomitant drugs defined as any drugs apart from 
antiretroviral drugs of the current regimen, i.e., co-
trimoxazole, fluconazole, anti-tuberculosis drugs, anti-
hypertensive drugs, and lipid-lowering agents.  
  To obtain an unbiased estimate of sample population, 
60% of study population was randomly selected from a total 
study population as a training set. The rest was used as a 
validation set. Demographic and clinical data were retrieved 
and reviewed retrospectively as previously described [15]. 
The study was approved by the Institutional Review Board.  
Statistical Analysis 
  Continuous variables with normal distribution are 
presented as mean and standard deviation (SD) and those 
with non-normal distribution are shown as median and 
interquartile range (IQR). Continuous variables were 
compared between groups using independent t-test or Mann-
Whitney U test. Continuous variables were divided into 
categories to facilitate risk estimation according to the 
distribution of the variables as well as clinical significance. 
Age was categorized into <35 vs >35 years old, body weight 
was categorized into <55 vs >55 kg., and CD4 cell counts 
were categorized into <100 vs >100 cells/mm
3. Categorical 
variables are shown as frequency and percentage. Chi-square 
test or Fisher’s exact test was used for analysis where 
appropriate for categorical ones.  
  Simple logistic regression analysis was used to determine 
the association between risk factors and outcome (presence 
of NVP-associated rash). Variables that presented p<0.25, 
were considered in a multiple logistic regression model after 
assessment of multicollinearity of variance inflation factors. 
We also considered two more variables, gender [11, 25-27] 
and previous AIDS-defining illness [15], that had been 
reported as the risk factors for NVP-associated rash in the 
model. Variables were selected into a multiple logistic 
regression model with backward selection. The model was 
reduced by excluding
 variables with p>0.05 in order to retain 
a simpler diagnostic
  model containing only the strongest 
determinants of NVP-associated skin rash. Thus, variables 
that attained a level of significance (p<0.05) were retained in 
the model [28]. We then compared the final model from 
backward selection with the initial model by using a 
likelihood ratio test and Akaike's information criterion. A 
weighted risk score was constructed using logistic regression 
coefficients. These coefficients were converted into scores 
by multiplying by ten and rounded off to the nearest whole 
number that were added up to obtain an aggregated score 
[29].  
  Two performance indexes were used to estimate the 
discrimination and calibration of the predictive model. The 
discrimination was evaluated using the area under the 
receiver-operator characteristic (ROC) curve [30] and the 
calibration was measured using the Pearson’s goodness-of-fit 
test. An area under the ROC curve of 1.0 is ideal whereas it 
is <0.5 indicates no diagnostic accuracy. In general, the area 
under the ROC curve >0.7 indicates a useful test [31]. The 
Pearson’s goodness-of-fit test has a p-value of >0.05 is 
considered being the good calibration model. The optimum 
cut-off point for the score was determined by sensitivity, 
specificity, positive predictive value, and negative predictive 
value. A p-value <0.05 was considered statistically 
significance. All statistical analyses were performed using 
Stata statistical software version 10.0 (Stata Statistical 
Software: Release 10.0, Stata Corporation, College Station, 
TX, 2007).  
RESULTS 
  Initially, 383 patients were included in the study but 13 
(3.4%) patients were excluded because of missing clinical 
data of interests. The derivation group from random 
sampling was further analyzed. A total of 222 patients with a 
median (IQR) age of 35.2 (31.1-42.0) years were in a 
training set. Of these, 116 (52.2%) were males and median 
(IQR) body weight was 54.0 (48.0-63.0) kg. The most 
common route of HIV acquisition was heterosexual (98%). 
Thirty-two (14.4%) patients had a history of drug allergy and 
134 (60.4%) patients receiving concomitant drug(s). Median 
(IQR) CD4 cell count at time of NVP initiation was 104 (35-
225) cells/mm
3. Prior to NVP initiation, 154 (69.4%) patients 
were naive to ART. Slow dose escalation of NVP was 
prescribed in 151 (68.0%) patients. 26    The Open AIDS Journal, 2009, Volume 3  Kiertiburanakul et al. 
  There were 72 patients in “rash” group and 150 patients 
in “no rash” group. Of 72 patients, 34, 35, and 3 patients 
developed grade 2, 3, and 4 of rash according to Division of 
AIDS table for grading the severity of adult and pediatric 
adverse events [32]. In rash group, a higher proportion of 
male gender (52.8% vs 45.3%, p = 0.318), patients with a 
history of drug allergy (25.0% vs 9.3%, p = 0.004), and 
switching from efavirenz (EFV) (26.4% vs 16.7%, p = 
0.106) were found. In contrast, patients without rash had a 
higher proportion of receiving concomitant drug(s) (66.7% 
vs 47.2%, p = 0.008), naive to ART (75.3% vs 56.9%, p = 
0.008), and prescribed slow dose escalation of NVP (74.0% 
vs 55.6%, p = 0.009). Median CD4 cell count at the time of 
NVP initiation was higher among patients in rash group (191 
vs 72 cells/mm
3, p = 0.001). Baseline demographics and 
clinical characteristics of patients by NVP-associated rash 
status are shown in Table 1.  
  We found five factors related to NVP-associated rash by 
simple logistic regression. These were a history of drug 
allergy (odds ratio (OR) 3.24, 95% confidence interval (CI), 
1.50-6.97, p = 0.003), no concomitant drug(s) (OR 2.24, 
95% CI, 1.26-3.97, p = 0.006), naive to ART (OR 2.31, 95% 
CI, 1.27-4.19, p = 0.006), not receiving slow dose escalation 
of NVP (OR 2.28, 95% CI, 1.26-4.11, p = 0.006), and CD4 
cell counts at time of NVP initiation >100 cells/mm
3 (OR 
2.69, 95% CI, 1.49-4.83, p = 0.001) (Table 2).  
  In multiple logistic regression, the independent predictor 
variables of NVP-associated rash are shown in Table 3. 
These were a history of drug allergy (OR 4.01, 95% CI, 
1.75-9.20, p = 0.001), no concomitant drug(s) (OR 2.48, 
95% CI, 1.32-4.64, p = 0.005), body weight <55 kg. (OR 
2.02, 95% CI, 1.09-3.76, p = 0.026), and not receiving slow 
dose escalation of NVP (OR 2.00, 95% CI, 1.06-3.77, p = 
0.032). A ROC curve was plotted to determine the ability of 
the model for correctly predicting the NVP-associated rash. 
The area under the ROC curve was 71%, indicating good 
model discriminatory power between individuals with and 
without rash (Fig. 1). The Pearson’s goodness-of-fit statistic 
value was 6.48 (p = 0.840), indicating excellent model 
calibration for the observed versus the predicted outcome. 
When the model was applied to the remaining 148 patients 
who comprised the validation set, the model still showed 
good calibration (Pearson’s goodness-of-fit statistic of 15.61, 
p = 0.156) and fair discrimination (area under the ROC curve 
of 65%). 
  A numerical score was formulated by using logistic 
regression coefficients for risk score calculation. A history of 
drug allergy, body weight <55 kg., not receiving slow dose 
escalation of NVP, and no concomitant drug(s) were 
assigned scores of 14, 9, 7 and 7, respectively. The equation 
used for the NVP-associated rash risk score calculation for 
each patient was: NVP-associated rash risk score = 14   
 
Table 1.  Baseline Demographics and Clinical Characteristics of Patients by Nevirapine-Associated Rash Status 
 
Variables  Total 
(n = 222) 
Rash 
(n = 72) 
No Rash 
(n = 150) 
P-Value 
Age, median (IQR), years  35.2 
(31.1-42.0) 
35.0 
(31.2-40.6)  
35.2 
(30.9-42.2)  0.918 
Male, n (%)  116 
(52.2) 
38 
(52.8) 
68 
(45.3)  0.318 
Body weight, median (IQR), kg.   54.0 
(48.0-63.0) 
53.0 
(48.0-59.0) 
55.0 
(48.0-65.0)  0.918 
HIV transmission by heterosexual, n (%)   217 
(97.8) 
69 
(95.8) 
148 
(98.7)  0.227 
History of AIDS-defining illness, n (%)  107 
(48.2) 
31 
(43.1) 
76 
(50.7)  0.317 
Concomitant other underlying illness(s), n (%)  32 
(14.4) 
13 
(18.1) 
19 
(12.7)  0.310 
History of drug allergy, n (%)  32 
(14.4) 
18 
(25.0) 
14 
(9.3)  0.004 
Receiving concomitant drug(s), n (%)  134 
(60.4) 
34 
(47.2) 
100 
(66.7)  0.008 
Naive to antiretroviral therapy, n (%)  154 
(69.4) 
41 
(56.9) 
113 
(75.3)  0.008 
Switching from efavirenz, n (%)  44 
(29.8) 
19 
(26.4) 
25 
(16.7)  0.106 
Receiving slow dose escalation of NVP, n (%)  151 
(68.0) 
40 
(55.6) 
111 
(74.0)  0.009 
CD4 cell count at time of NVP initiation, median (IQR), cells/mm
3   104 
(35-225) 
191 
(61-290) 
72 
(23-200)  0.001 
Abbreviation: IQR, interquartile range, NVP, nevirapine. Prediction for Nevirapine-Associated Rash  The Open AIDS Journal, 2009, Volume 3    27 
 
 
Table 2.  Simple Logistic Regression Analysis of the Variables Related to Nevirapine-associated Rash 
 
Variables  Odds Ratio  95% CI  P-Value 
Male gender  1.35 0.77-2.37  0.299 
Age (>35 vs <35 years old)  0.97 0.56-1.71  0.926 
Body weight (<55 vs >55 kg.)  1.72 0.97-3.07  0.065 
HIV transmission by heterosexual  0.31  0.05-1.90  0.206 
History of AIDS-defining illness   0.74  0.42-1.30  0.289 
Concomitant other underlying illness(s)   1.52  0.70-3.28  0.287 
History of drug allergy  3.24 1.50-6.97  0.003 
No concomitant drug(s)   2.24 1.26-3.97  0.006 
Naive to antiretroviral therapy   2.31 1.27-4.19  0.006 
Switching from efavirenz   1.79 0.91-3.53  0.091 
Not receiving slow dose escalation of NVP   2.28  1.26-4.11  0.006 
CD4 cell count at time of NVP initiation (>100 vs <100 cells/mm
3) 2.69  1.49-4.83  0.001 
Abbreviation: CI, confidence interval, NVP, nevirapine. 
 
Table 3.  Multiple Logistic Regression Analysis of the Variables Related to Nevirapine-Associated Rash 
 
Variables  Estimated Regression Coefficient 
(Standard Error)  Odds Ratio  95% CI  P-Value Score  (Points)  
History of drug allergy   1.38 (0.42)  4.01  1.75-9.20  0.001  14 
No concomitant drug(s)  0.91 (0.32)  2.48  1.32-4.64  0.005  9 
Body weight (<55 vs >55 kg.)  0.70 (0.32)  2.02  1.09-3.76  0.026  7 
Not receiving slow dose escalation of NVP   0.69 (0.32)  2.00  1.06-3.77  0.032  7 
Abbreviation: CI, confidence interval, NVP, nevirapine. 
 
 
Fig. (1). Receiver-operator characteristic (ROC) plot of the model composed of a history of drug allergy, body weight <55 kg., not receiving 
slow dose escalation, and no concomitant drug(s). 
0
.
0
0
0
.
2
5
0
.
5
0
0
.
7
5
1
.
0
0
S
e
n
s
i
t
i
v
i
t
y
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.713428    The Open AIDS Journal, 2009, Volume 3  Kiertiburanakul et al. 
 (a history of drug allergy) + 9 (no concomitant drug(s)) + 7 
(body weight <55 kg.) + 7 (not receiving slow dose 
escalation of NVP). For each of the variables, a value of “1” 
was assigned if the variable was present or “0” of it was 
absent. The median (IQR) risk score of patients in rash group 
and no rash group was 16 (9-22) points and 7 (7-16) points, 
respectively (p<0.001). The distribution of risk score among 
HIV-infected patients with and without NVP-associated rash 
is shown in Table 4. If the total score was >21 points, the 
individual was defined as high risk for NVP-associated rash, 
otherwise was low risk. There were 22 of 72 (30.6%) 
patients in rash group and 15 of 150 (10.0%) had a risk score 
above the cutoff who were defined as high risk individuals 
(p<0.001). A cutoff at 21 points yielded specificity and 
positive predictive value of 99% and 69%, respectively. In 
addition, patients who had a risk score >21 points had odds 
of NVP-associated rash 3.96 times higher than those who 
had a score of <21 points (OR 3.96, 95% CI, 1.79-8.86, p = 
0.001). 
Table  4.  Distribution of HIV-Infected Patients with and 
without Nevirapine-Associated Rash in Relation to 
the Risk Score Obtained 
 
Risk  
Score 
Rash 
n (%) 
No Rash 
n (%) 
Total 
n (%) 
0   3 
(4.2) 
31 
(20.7) 
34 
(15.3) 
7  14 
(19.4) 
50 
(33.3) 
64 
(28.8) 
9  4 
(5.6) 
16 
(10.8) 
20 
(9.0) 
14  9 
(12.4) 
14 
(9.4) 
23 
(10.4) 
16  20 
(27.8) 
24 
(16.0) 
44 
(19.8) 
21  4 
(5.6) 
2 
(1.3) 
6 
(2.7) 
23  9 
(12.4) 
8 
(5.3) 
17 
(7.7) 
28  4 
(5.6) 
3 
(2.0) 
7 
(3.2) 
30  4 
(5.6) 
1 
(0.7) 
5 
(2.2) 
37  1 
(1.4) 
1 
(0.7) 
2 
(0.9) 
Total  72 
(100.0)  150 (100.0)  222 
(100.0) 
The equation used for the NVP-associated rash risk score calculation: NVP-associated 
rash risk score = 14 (a history of drug allergy) + 9 (no concomitant drug(s)) + 7 (body 
weight <55 kg.) + 7 (not receiving slow dose escalation of NVP) 
 
DISCUSSION 
  The present study was the first one, which was conducted 
to develop prediction model and risk score for NVP-
associated rash in advanced HIV-infected patients. 
Approximately half of the patients had a history of AIDS-
defining illness and the median CD4 cell count at time of 
NVP initiation was approximately 100 cells/mm
3. This study 
well represented the target population in resource-
constrained settings. According to clinical characteristics 
between the two groups, there was a lower proportion of 
patients prescribed slow dose escalation of NVP in rash 
group (55.6% vs 74.0%, p = 0.009). Furthermore, patients in 
rash group also had a higher proportion of switching EFV to 
NVP but there was no statistically significant difference 
(26.4%  vs 16.7%). These two factors might be correlated 
because when changing from EFV to NVP, full dose of NVP 
should be started. Slow dose escalation of NVP after EFV 
treatment can lead to lower therapeutic plasma drug levels 
because EFV induces the metabolism of co-administered 
drugs through the induction of CYP 3A4 as it has been 
shown in a pharmacokinetic study [33]. However, 
multicollinearity was not found after variance inflation 
factors assessment of these 2 variables. 
  We found four independent factors associated with rash, 
namely a history of drug allergy, no concomitant drug(s), 
body weight <55 kg., and not receiving slow dose escalation. 
These factors had been reported as related factors for NVP-
associated rash in the previous studies [13, 15, 17, 20, 34]. 
Patients who had a history of drug allergy had been reported 
as a risk factor of NVP-associated rash among Thai HIV-
infected patients, especially those who had a history of 
sulfamethoxazole allergy [34]. Patients who took 
concomitant drug(s), which mostly (88.8%) were 
fluconazole and co-trimoxazole (data not shown), might 
have lower NVP plasma level than normal value due to 
enzyme induction of, especially, fluconazole [35]. The 
probable higher plasma NVP level might explain why 
patients who did not take concomitant drug(s) had a higher 
risk of rash. In addition, patients who were not taking other 
medications had a lower proportion of previous AIDS-
defining illness (31.8% vs 59.0%, p<0.001) (data not shown) 
which reflected in higher CD4 cell counts. Both AIDS-
defining illness and high CD4 cell counts at the time of NVP 
initiation were found to be associated with NVP-associated 
rash in the previous study [15]. Patients with higher body 
weight might have lower NVP plasma concentration and 
linked to lower risk of NVP-associated rash [36]. Clearly, 
slow dose escalation of NVP minimizes the risk for toxicity 
[13, 20]. 
  No association between gender and CD4 cell count and 
risk of NVP-associated rash were observed in the present 
study even though these two factors were consistently 
reported in some studies [11-16]. We did not find any 
association between gender and risk of rash in our previous 
study using the same cohort [15]. CD4 cell count was 
associated with rash in simple logistic regression analysis of 
our present data, but it was not a risk factor after control of 
other variables. 
  Despite the fact that NVP-based regimen is the most 
commonly use in many countries, there was no model 
developed for health care providers to guide and/or predict 
NVP-associated rash before prescribing NVP especially in 
resource-limited settings. These factors from our model 
could be combined to create a risk index and risk score for Prediction for Nevirapine-Associated Rash  The Open AIDS Journal, 2009, Volume 3    29 
predicting NVP-associated rash. Identifying risk factors 
associated with rash is relevant when health care provider 
need to prescribe NVP to HIV-infected patients. Counseling 
and informing patients regarding risk of rash associated with 
NVP is crucial for prevention the consequence from NVP 
adverse effects including adherence improvement [37]. This 
particular model was developed by selecting the significant 
factors from logistic regression analysis including factors 
that had an a priori biological and/or clinical rationale. A 
weighted risk score was constructed using logistic regression 
coefficients. Selecting the final model based on the statistical 
criteria for good discrimination and calibration of the 
predictive model. This model considered to be a good 
candidate, despite the decreased area under the ROC curve 
of the validation set. The model is “over-optimism” [38], i.e. 
the area under the curve will almost always be worse in the 
validation set than training set. The risk score is also 
developed for predicting risk of NVP-associated rash. This 
relative simple risk score, with the cutoff >21 points, showed 
a high specificity and positive predictive value. If patients 
had a risk score of >21, either EFV or PIs should be 
considered as an alternative in the resource limitation 
because of a high risk of NVP-associated rash. However, 
physicians should discuss risk and benefit, including close 
follow-up patients. High risk of unsuccessful switching from 
NVP to EFV was found in patients who had a history of drug 
allergy apart from NVP and had CD4 cell counts less than 
100 cells/mm
3 [39]. In the resource-limited settings, where 
both EFV and PIs are not available, or patients cannot 
tolerate both EFV and PIs, NVP might be used with caution, 
including slow dose escalation, closed monitoring of both 
clinical and liver function tests after assessing risk and 
benefit. 
  The present study had some limitations. First, there were 
some missing data, but it was a small proportion, and we 
excluded these patients from the analysis. However, we 
believed that model-wise deletion analysis for defining the 
prediction model was not bias. Second, we included only 
clinical characteristics and CD4 cell count in the model 
because these variables can apply to most of HIV-infected 
patients in resource-limited settings. Some laboratory 
variables may improve the discrimination power if they were 
added in the model. Third, we had to categorize continuous 
variables into category ones for the model building and the 
pre-defined cut point was arbitrary decision. This might 
loose information and significant association between 
variables and outcome. Last, this study was conducted 
among Thai patients, which tended to have a relative higher 
prevalence of NVP-associated rash. High prevalence of NVP 
rash in Thai patients might be explained by genetic factor. 
Our group recently found the strong association of HLA-
B*3505  allele among Thai HIV-infected patients who 
developed NVP-associated rash [40]. Thus, generalization of 
these findings to other races should be considered cautiously. 
  In conclusion, a model and risk score for predicting 
NVP-associated rash among HIV-infected performed well in 
this particular study population. It might be useful for 
predicting the risk of rash before NVP initiation among HIV-
infected patients with low CD4 cell counts especially in 
resource-limited setting where NVP is widely used. It is also 
important to monitor NVP-associated rash among HIV-
infected patients with a history of drug allergy, low body 
weight (<55 kg), not receiving slow dose escalation, and 
concomitant drug(s). In addition, further validation of this 
model and risk score in other populations is required. 
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